Damora Therapeutics (DMRA) Accumulated Expenses (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly Accumulated Expenses came in at $6.0 million in Q1 2026, up 401.0% YoY from $1.2 million in Q1 2025, and up 149.77% on a QoQ basis from $2.4 million in Q4 2025.
Damora Therapeutics (DMRA) Accumulated Expenses (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of Accumulated Expenses data on file, last reported at $6.0 million in Q1 2026.
- Quarterly Accumulated Expenses rose 401.0% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (up 401.0% YoY) and the FY2025 annual result came in at $2.4 million, up 192.8% from the prior year.
- Accumulated Expenses climbed to $6.0 million in Q1 2026, from $2.4 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $10.5 million in Q1 2023 to a low of $820000.0 in Q4 2024.
- A 5-year average of $4.6 million and a median of $4.0 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Accumulated Expenses plunged 80.14% — and 2026, when it soared 401.0%.
- Tracing DMRA's Accumulated Expenses over 5 years: stood at $7.8 million in 2022, then tumbled by 46.78% to $4.1 million in 2023, then sank by 80.14% to $820000.0 in 2024, then soared by 192.8% to $2.4 million in 2025, then jumped by 149.77% to $6.0 million in 2026.
- The last three Accumulated Expenses figures came in at $6.0 million (Q1 2026), $2.4 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.88 Mn |
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 820,000.00 |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Dec 31, 2023 | 4.13 Mn |
| Sep 30, 2023 | 8.08 Mn |
| Jun 30, 2023 | 9.34 Mn |
| Mar 31, 2023 | 10.51 Mn |
| Dec 31, 2022 | 7.76 Mn |
| Sep 30, 2022 | 6.95 Mn |
| Jun 30, 2022 | 4.67 Mn |
| Mar 31, 2022 | 4.00 Mn |
| Dec 31, 2021 | 3.01 Mn |
| Sep 30, 2021 | 3.76 Mn |